Carbon Biosciences Announces Four Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting
WALTHAM, Mass., May 2, 2024 /PRNewswire/ -- Carbon Biosciences, a preclinical stage biotechnology company developing genetic medicines for the treatment of pulmonary and cardiac diseases, announced that it has been selected for an oral presentation at the Presidential Symposium during the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting taking place from May 7-11, 2024, in Baltimore, MD. The presentation will highlight the development of CGT-001, a potential gene therapy for the treatment of Cystic Fibrosis (CF), which utilizes the novel pulmonary targeting vector, CBN-1000, capable of delivering genes beyond the capacity of AAV. In addition, the Company will be featuring three poster presentations detailing new preclinical data, and manufacturing process development and analytical characterization for two of its novel viral gene therapy vectors.
- In addition, the Company will be featuring three poster presentations detailing new preclinical data, and manufacturing process development and analytical characterization for two of its novel viral gene therapy vectors.
- Key insights from Carbon Biosciences' presentations at ASGCT:
CBN-1000, a non-AAV parvovirus-based gene therapy vector, demonstrates excellent tolerability and transgene expression throughout the lung and airway in nonhuman primates after nebulization. - CBN-1100 vector demonstrates transgene packaging of up to 5.9 kb, representing >1 kb more capacity than AAV vectors.
- The complete absence of expression in the liver suggests the potential for a differentiated specificity and safety profile compared to AAV-based vectors for cardiac gene therapy.